Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01215136
Title First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Hoosier Cancer Research Network
Indications

urethra transitional cell carcinoma

ureter transitional cell carcinoma

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

Therapies

Everolimus

Paclitaxel

Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
University of Alabama Hematology Oncology Clinic at Medical West Birmingham Alabama 35294 United States Details
Northwestern University, Robert H. Lurie Comprehensive Cancer Center Chicago Illinois 60611 United States Details
Cancer Care Center of Southern Indiana Bloomington Indiana 47403 United States Details
Indiana University Melvin and Bren Simon Cancer Center Indianapolis Indiana 46202 United States Details
IU Health Central Indiana Cancer Centers Indianapolis Indiana 46219 United States Details
Metro Health Cancer Care Wyoming Michigan 49519 United States Details
Nebraska Cancer Specialists Omaha Nebraska 68114 United States Details
Icahn School of Medicine: Tisch Cancer Institute at Mount Sinai Medical Center New York New York 10029 United States Details
MUSC Hollings Cancer Center Charleston South Carolina 29425 United States Details
University of Texas Medical Branch Galveston Texas 77555 United States Details
Virginia Oncology Associates Norfolk Virginia 23502 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field